News articles about BioTelemetry (NASDAQ:BEAT) have trended somewhat positive recently, Accern Sentiment reports. The research firm ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. BioTelemetry earned a media sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the medical research company an impact score of 45.9587527360842 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the news stories that may have impacted Accern’s rankings:
- Advice by Analysts to Buy Healthcare Stock: BioTelemetry, Inc. (BEAT) ,Sunesis Pharmaceuticals, Inc. (SNSS) - Street Observer (press release) (streetobserver.com)
- Watching The Trendlines for BioTelemetry Inc (BEAT) - Evergreen Caller (evergreencaller.com)
- Cummins Inc. (CMI) Position Boosted by Legal & General Group Plc (newstrendstoday.com)
- Stock Performance Review on Medical Laboratories & Research Industry — Cancer Genetics, BioTelemetry, Organovo, and Bruker (bizjournals.com)
- Stock Performance Review on Medical Laboratories & Research Industry — Cancer Genetics, BioTelemetry, Organovo … - Markets Insider (markets.businessinsider.com)
Shares of BioTelemetry (NASDAQ BEAT) traded up 1.49% during trading on Friday, hitting $33.95. 327,750 shares of the company traded hands. BioTelemetry has a 52-week low of $15.25 and a 52-week high of $35.75. The company has a 50-day moving average of $32.42 and a 200-day moving average of $28.64. The stock has a market capitalization of $972.84 million, a PE ratio of 20.96 and a beta of 0.76.
BioTelemetry (NASDAQ:BEAT) last posted its quarterly earnings data on Wednesday, May 3rd. The medical research company reported $0.16 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.02. BioTelemetry had a return on equity of 19.87% and a net margin of 22.77%. The company had revenue of $55.88 million for the quarter, compared to the consensus estimate of $55.11 million. Equities analysts expect that BioTelemetry will post $0.88 EPS for the current year.
Several brokerages have issued reports on BEAT. BidaskClub cut shares of BioTelemetry from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Benchmark Co. raised their price target on shares of BioTelemetry from $38.00 to $44.00 and gave the company a “buy” rating in a report on Wednesday, July 19th. Zacks Investment Research upgraded shares of BioTelemetry from a “hold” rating to a “buy” rating and set a $38.00 price target on the stock in a report on Tuesday, May 2nd. Lake Street Capital restated a “buy” rating and issued a $50.00 price target (up from $35.00) on shares of BioTelemetry in a report on Friday, July 14th. Finally, Dougherty & Co raised their price target on shares of BioTelemetry from $30.00 to $37.00 and gave the company a “buy” rating in a report on Tuesday, April 11th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. BioTelemetry currently has an average rating of “Buy” and a consensus target price of $39.20.
In other news, Director Robert J. Rubin sold 15,000 shares of the business’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $28.14, for a total value of $422,100.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 9.60% of the stock is currently owned by insiders.
BioTelemetry Company Profile
BioTelemetry, Inc (BioTelemetry), formerly CardioNet, Inc, provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting.
Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
